Trials / Unknown
UnknownNCT03545607
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Healios K.K. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MultiStem | single intravenous infusion 18-36 hours after stroke |
| BIOLOGICAL | Placebo | single intravenous infusion 18-36 hours after stroke |
Timeline
- Start date
- 2018-07-28
- Primary completion
- 2022-09-01
- Completion
- 2023-06-01
- First posted
- 2018-06-04
- Last updated
- 2022-02-09
Locations
26 sites across 2 countries: United States, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03545607. Inclusion in this directory is not an endorsement.